Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05014815. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study identification
- NCT ID
- NCT05014815
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- BeiGene
- Industry
- Enrollment
- 272 participants
Conditions and interventions
Conditions
Interventions
- Ociperlimab Drug
- Tislelizumab Drug
- Carboplatin Drug
- Paclitaxel Drug
- Nab paclitaxel Drug
- Cisplatin Drug
- Pemetrexed Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2021
- Primary completion
- Sep 3, 2024
- Completion
- Sep 3, 2024
- Last update posted
- Sep 15, 2025
2021 – 2024
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valkyrie Clinical Trials | Los Angeles | California | 90067-2011 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242-1009 | — |
| Comprehensive Cancer Center of Nevada | Las Vegas | Nevada | 89169-3321 | — |
| Rj Zuckerberg Cancer Center | New Hyde Park | New York | 11042-1118 | — |
| North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists (New York) | New York | New York | 10028-0517 | — |
| North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists | Port Jefferson Station | New York | 11776-8066 | — |
| Ny Cancer and Blood Specialists | The Bronx | New York | 10469-5930 | — |
| Xcancerdayton Physician Network | Dayton | Ohio | 45409-1328 | — |
| Tennessee Cancer Specialist | Knoxville | Tennessee | 37909-1327 | — |
| Texas Oncology Tyler Longview | Austin | Texas | 78705-1163 | — |
| Cancer Care Northwest | Spokane Valley | Washington | 99216-1020 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05014815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2025 · Synced Jul 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05014815 live on ClinicalTrials.gov.